ClinicalTrials.gov
ClinicalTrials.gov Menu

Determination of Effective Vitamin D Replacement and Monitoring Strategies in Vitamin D Deficiency State (EVIREST-D)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01430793
Recruitment Status : Completed
First Posted : September 8, 2011
Last Update Posted : April 8, 2014
Sponsor:
Information provided by (Responsible Party):
Muhammad Qamar Masood, Aga Khan University

Brief Summary:

The purpose of the study is determination of effective vitamin D replacement strategy in vitamin D deficiency states with currently available preparations in Pakistan & to determine the cost effective monitoring strategy with urinary calcium excretion serving as a surrogate marker of achievement of vitamin D sufficiency state.

The study will be conducted at the out-patient Endocrinology Clinics of the Aga Khan University Hospital, Karachi, Pakistan. All patients seen in endocrine clinics with Vitamin D level less than 20 ng and do not have any of exclusion criteria mentioned below will be eligible for recruitment in the study. The study participants will be randomly assigned into 4 groups for intervention to receive intramuscular or oral Vitamin D in 200,000 or 600,000 units as per group allocation. Each group will comprise of 25 participants.

Group 1: Vitamin D3 600,000 units IM and then every 2 monthly for 2 times if levels remain < 30 ng/ml.

Group 2: Vitamin D3 600,000 units orally and then every 2 monthly for 2 times if levels remain < 30 ng/ml.

Group 3: Vitamin D3 200,000 units IM initially and then every 2 monthly for 2 months if levels remain < 30 ng/ml.

Group 4: Vitamin D3 200,000 units orally initially and then every 2 monthly for 2 times if levels remain < 30 ng/ml.

All patients will be prescribed elemental Calcium 1 gram /day. Vitamin D levels along with the other biochemical parameter and random urine for calcium & creatinine will be checked at 00, 02, 04, 06 and 12 months.


Condition or disease Intervention/treatment Phase
Vitamin D Deficiency Drug: Vitamin D3 600,000 units IM Drug: Vitamin D3 600,000 Orally Drug: Vitamin D3 200,000 units IM Drug: Vitamin D3 200,000 Orally Not Applicable

  Show Detailed Description

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 99 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Vitamin D Dosing and Monitoring Study
Study Start Date : November 2011
Actual Primary Completion Date : March 2013
Actual Study Completion Date : March 2013

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Active Comparator: Vitamin D 600,000 IM
Vitamin D3 600,000 units will be given by intramuscular injection
Drug: Vitamin D3 600,000 units IM
Vitamin D3 600,000 units will be given by Intramuscular injection and then will be repeated every 2 monthly for 2 times if vitamin D levels remain < 30 ng/ml
Other Name: Cholecalciferol

Active Comparator: Vitamin D 600,000 orally
Vitamin D3 600,000 units will be given orally
Drug: Vitamin D3 600,000 Orally
Vitamin D3 600,000 units will be given orally and then will be repeated every 2 monthly for 2 times if vitamin D levels remain < 30 ng/ml
Other Name: Cholecalciferol

Active Comparator: Vitamin D 200,000 IM
Vitamin D3 600,000 units will be given by intramuscular injection
Drug: Vitamin D3 200,000 units IM
Vitamin D3 200,000 units will be given by Intramuscular injection and then will be repeated every 2 monthly for 2 times if level of vitamin D remain < 30 ng/ml
Other Name: Cholecalciferol

Active Comparator: Vitamin D 200,000 orally
Vitamin D 200,000 units will be given orally
Drug: Vitamin D3 200,000 Orally
Vitamin D3 200,000 units will be given by orally and then will be repeated every 2 monthly for 2 times if level of vitamin D remain < 30 ng/ml
Other Name: Cholecalciferol




Primary Outcome Measures :
  1. Change in vitamin D levels with specified dose and route of administration, at define intervals [ Time Frame: 02, 04, 06 and12 months ]

Secondary Outcome Measures :
  1. Differences in the random urinary calcium to creatinine ratio in the untreated and treated state and its correlation with vitamin D levels [ Time Frame: 00, 02, 04, 06 and 12 months ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • All patients with Vitamin D level less than 20 ng/dl

Exclusion Criteria:

  • Patients who have received vitamin D injection in last 03 months.
  • Patients with hypercalcemia (corrected calcium > 10.6 mg/dl)
  • Known Malignancy.
  • Known case of CLD or serum ALT > 3 times ULN
  • Patients with creatinine > 2.0 mg/dl.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01430793


Locations
Pakistan
Aga Khan University Hospital
Karachi, Sind, Pakistan, 74800
Sponsors and Collaborators
Aga Khan University
Investigators
Principal Investigator: Muhammad Q Masood, MBBS; FACP Aga Khan University
Study Chair: Abdul Jabbar, MBBS; FRCP Aga Khan University
Study Director: Aysha Habib, MBBS; FCPS Aga Khan University

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Muhammad Qamar Masood, Assistant Professor, Department of Medicine, Aga Khan University
ClinicalTrials.gov Identifier: NCT01430793     History of Changes
Other Study ID Numbers: SM100404
First Posted: September 8, 2011    Key Record Dates
Last Update Posted: April 8, 2014
Last Verified: April 2014

Additional relevant MeSH terms:
Vitamin D Deficiency
Avitaminosis
Deficiency Diseases
Malnutrition
Nutrition Disorders
Vitamins
Vitamin D
Ergocalciferols
Cholecalciferol
Micronutrients
Growth Substances
Physiological Effects of Drugs
Bone Density Conservation Agents